eligibility_summary
Adults (≥18) with advanced/metastatic NSCLC harboring METex14 skipping or MET amplification/overexpression (tissue/ctDNA/IHC), ECOG 0–1, measurable disease, stable brain mets, able to take oral drug. Prior chemo/IO allowed, adequate labs, pregnancy/contraception required. Exclude: prior MET TKI in TKI‑naïve cohort, other driver with prior targeted therapy, active HBV/HCV/HIV, significant CV disease, uncontrolled illness/O2, unstable eye disease, ILD/pneumonitis, unresolved >G1 AEs, most other cancers.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06083857 tests amivantamab + tepotinib in advanced MET‑altered NSCLC (MET exon 14 skipping, MET amplification/overexpression). Amivantamab: bispecific IgG1 monoclonal antibody targeting EGFR and MET, blocks ligand/receptor interactions, drives receptor internalization/degradation, and engages immune effector functions (ADCC/ADCP). Tepotinib: oral, selective small‑molecule MET tyrosine kinase inhibitor, suppresses MET phosphorylation and downstream MAPK/PI3K/AKT signaling. Target cells/pathways: tumor cells with MET dysregulation, MET/HGF and EGFR pathways and downstream signaling. Exploratory: immunomodulatory effects and resistance via ctDNA/tissue profiling.